Zobrazeno 1 - 10
of 242
pro vyhledávání: '"Michael C, Perry"'
Autor:
Zhongwu Lai, Darren Hodgson, Brian Dougherty, J. Carl Barrett, Tsveta Milenkova, Elizabeth A. Harrington, Jessica S Brown, Eric Pujade-Lauraine, Simon Dearden, Alexandra Leary, Jerry S. Lanchbury, Michael C. Perry, Cathy E. Elks, Kirsten Timms
Publikováno v:
Gynecologic oncology. 163(3)
Objective Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain regarding tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f015e6502a0b6bdc67dd4e5e6c4f5aa9
https://pubmed.ncbi.nlm.nih.gov/34742578
https://pubmed.ncbi.nlm.nih.gov/34742578
Autor:
Michael C. Perry, Jerry S. Lanchbury, Kirsten Timms, Robert S. Brown, Gordon B. Mills, Alexander Gutin
Publikováno v:
Journal of Clinical Oncology. 38:1586-1586
1586 Background: Clinical trials have explored the utility of various genomic instability (GI) scores or gene panels to assess deficiencies in the homologous recombination (HR) DNA repair pathway and support PARP inhibitor use in ovarian cancer; howe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1227e434fb28cf6f0732d664ff63d7d6
https://doi.org/10.1200/jco.2020.38.15_suppl.1586
https://doi.org/10.1200/jco.2020.38.15_suppl.1586
Publikováno v:
ACI Structural Journal. 115
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b253a9e16c12023f9cc373be3d13b87b
https://doi.org/10.14359/51701914
https://doi.org/10.14359/51701914
Autor:
Alexander Gutin, Robert S. Brown, Hani Gabra, Euan A. Stronach, Kirsten Timms, Elisha Hughes, Xinxue Liu, Krystal Brown, Jerry S. Lanchbury, James Paul, Mona El-Bahrawy, Christopher Neff, Michael C. Perry, Jennifer H. Steel, Liz-Anne Lewsley, Nadeem Siddiqui
The current study evaluated three biomarkers [homologous recombination deficiency (HRD), tumor BRCA1/2 (tBRCA) mutations, and CCNE1 copy-number variation (CNV)] in ovarian tumors from patients enrolled on the SCOTROC4 clinical trial for associations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::006e9f50a6351fc5f5fd22da369a6513
http://hdl.handle.net/10044/1/59251
http://hdl.handle.net/10044/1/59251
Autor:
James H. Dooley, Michael C. Perry
Publikováno v:
Journal of Environmental Solutions for Oil, Gas, and Mining. 1:84-99
INTRODUCTION Soil erosion is a significant risk during and after grading operations on mine and pipeline sites. A range of materials are commercially available to reduce the erosive effects of wind...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20f105a423c9be2f987dbcd6f9f7a6c5
https://doi.org/10.3992/2377-3545-1.2.84
https://doi.org/10.3992/2377-3545-1.2.84
Autor:
Andrey Zharkikh, Kirsten Timms, Zoltan Szallasi, Jerry S. Lanchbury, Michael C. Perry, Andrea L. Richardson, Nicolai Juul Birkbak, Alexander Gutin
Publikováno v:
Journal of Clinical Oncology. 37:2634-2634
2634 Background: Immune checkpoint inhibitors (ICI) block proteins which enable cancer cells to evade the immune system. Recent studies have shown that the higher the tumor mutation burden (TMB) the greater the likelihood of response to ICI therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9c34a9e80e85d4ca6000a4ee7d6db28
https://doi.org/10.1200/jco.2019.37.15_suppl.2634
https://doi.org/10.1200/jco.2019.37.15_suppl.2634
Autor:
Heather A. Wakelee, Joan H. Schiller, Michael C. Perry, Corey J. Langer, David H. Johnson, Julie R. Brahmer, Chandra P. Belani, Suzanne E. Dahlberg, Alan Sandler
Publikováno v:
Lung Cancer. 76:410-415
The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex.Eligible patients (N=1590) from E1594, a 4-arm platinum-based chemotherapy trial, and E4599 (carboplatin/paclitaxel ± bevacizumab) chemotherapy arm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61b4350987d5351194c5230c38b7fb0d
https://doi.org/10.1016/j.lungcan.2011.12.006
https://doi.org/10.1016/j.lungcan.2011.12.006
Autor:
Daniel M. Berney, Alexander Gutin, Jimmy Park, Jerry S. Lanchbury, David Mesher, Julia Reid, Christopher S. Foster, Henrik Møller, Adib Younus, Gabrielle Fisher, Michael C. Perry, Peter T. Scardino, Jack Cuzick, Steve Stone
Publikováno v:
British Journal of Cancer
Background: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by tra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::263e231154141dfeaea6cd80ed9aabbc
http://europepmc.org/articles/PMC3304411
http://europepmc.org/articles/PMC3304411
Publikováno v:
Clinical Lung Cancer. 12:148-154
Lung scar carcinoma (SC) was first described by Friedrich in 1939 as a type of lung cancer that originates around peripheral scars in the lung. Scarring in the lung can result from a variety of infections, injuries, and lung diseases. Scars can also
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::215d04c1f28721740bd4cd3b408c5500
https://doi.org/10.1016/j.cllc.2011.03.011
https://doi.org/10.1016/j.cllc.2011.03.011
Autor:
Michael C. Perry, Shadi Haddadin
Publikováno v:
Clinical Lung Cancer. 12:87-93
The history of small-cell lung cancer (SCLC) is one of the more fascinating stories of medicine, a story of hope and disappointment that characterizes it as 1 of the most elusive cancers. Its history can be divided into 3 intervals. The first interva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd6eb710e3fc2d6ae3e5a2c7ea862b5
https://doi.org/10.1016/j.cllc.2011.03.002
https://doi.org/10.1016/j.cllc.2011.03.002